Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum BB-46
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum BB-46 is a specific probiotic bacterial strain developed by Chr. Hansen. It is a primary active component of the multi-strain probiotic product Bifiform, where it is frequently formulated alongside Enterococcus faecium ENCfa-68. BB-46 is utilized for the management of various gastrointestinal disorders, most notably post-infectious irritable bowel syndrome (PI-IBS) and as an adjunct to Helicobacter pylori eradication therapy to mitigate antibiotic-associated dysbiosis and gastrointestinal side effects. The strain functions by restoring the balance of the intestinal microbiome, inhibiting the growth of opportunistic pathogens, and reducing mucosal inflammation as evidenced by decreased fecal calprotectin levels. Additionally, BB-46 promotes the production of beneficial metabolites, including short-chain fatty acids (SCFAs) like butyrate, and has been investigated for its potential to modulate obesity-related gut microbiota profiles.
- Brand names
- Bifiform
- Other names
- B. longum BB-46Bifidobacterium longum strain BB-46
Beyond the preview
Go deeper on bifidobacterium longum BB-46.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum BB-46.